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https://doi.org/10.1016/j.stemcr.2017.09.007SUMMARYHigh-purity cardiomyocytes (CMs) derived fromhuman induced pluripotent stem cells (hiPSCs) are promising for drug development and
myocardial regeneration. However, most hiPSC-derived CMs morphologically and functionally resemble immature rather than adult
CMs, which could hamper their application. Here, we obtained high-quality cardiac tissue-like constructs (CTLCs) by cultivating
hiPSC-CMs on low-thickness aligned nanofibers made of biodegradable poly(D,L-lactic-co-glycolic acid) polymer. We show that multi-
layered and elongated CMs could be organized at high density along aligned nanofibers in a simple one-step seeding process, resulting in
upregulated cardiac biomarkers and enhanced cardiac functions. When used for drug assessment, CTLCs were much more robust than
the 2D conventional control. We also demonstrated the potential of CTLCs for modeling engraftments in vitro and treating myocardial
infarction in vivo. Thus, we established a handy framework for cardiac tissue engineering, which holds high potential for pharmaceutical
and clinical applications.INTRODUCTION
Human pluripotent stem cells (hPSCs), including human
embryonic stem cells (hESCs) and human induced
pluripotent stem cells (hiPSCs), can be differentiated
into cardiomyocytes (hPSC-CMs), which offer a number
of advantages for drug development as well as for
myocardial regeneration (Matsa and Denning, 2012;
Liang et al., 2013; Chong et al., 2014; Kimbrel and Lanza,
2015; Feric and Radisic, 2016; Shinozawa et al., 2017).
However, although high-purity CM differentiation can
be achieved (Minami et al., 2012; Lian et al., 2013;
Burridge et al., 2014), the hPSC-CMs derived
under normal conditions are randomly distributed and
resemble immature rather than adult CMs, as demon-
strated by their morphological and functional character-
istics (Snir et al., 2003; Robertson et al., 2013; Matsa
et al., 2014). Accordingly, the reported 2D culture should
not be used for high-performance drug screening (Braam
et al., 2010; Guo et al., 2011; Matsa et al., 2011; Harris
et al., 2013; Liang et al., 2013; Navarrete et al., 2013).
More recent studies have been based on 3D CM tissue
construction, showing improved maturation with
respect to the 2D control (Huebsch et al., 2016; Jackman
et al., 2016; Mannhardt et al., 2016; Schwan et al., 2016).
In parallel, myocardial regeneration for repairing injured1546 Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017 j ª 2017
This is an open access article under the CC BY-NC-ND license (http://creativheart has progressed by using cell injections (Shiba et al.,
2012, 2016), cell sheets (Masumoto et al., 2012;
Kawamura et al., 2013), or cell patches (Menasche´
et al., 2015). However, the above in vivo studies were
mostly based on poorly organized hPSC-CMs (Shao
et al., 2015; Mathur et al., 2016), and only a few recent
investigations have paid attention to the 3D cellular
organization in engineered tissues, showing a longer-
term survival (Riegler et al., 2015) and improved ventric-
ular functions (Weinberger et al., 2016) after tissue
engraftment.
To reproduce the in vivo cardiac tissue organization,
nanofibers with high surface area to volume ratios were
used for cardiac tissue engineering (Zong et al., 2005;
Orlova et al., 2011; Hsiao et al., 2013; Joanne et al.,
2016). CMs on the aligned nanofibers can form, for
example, cell-elongated tissue-like constructs with
enhanced maturation (Han et al., 2016; Xu et al., 2017)
and improved ability to repair myocardial infarction
(MI) (Lin et al., 2014). Critical issues such as limited cell
infiltration in the nanofiber systems (Zong et al., 2005;
Yu et al., 2014), fiber layer thickness, fiber degradability,
and fiber stiffness remain to be addressed since they are
important for the implantation and treatment of
sustained re-entrant arrhythmias (Bursac et al., 2007) after
transplantation.The Authors.
ecommons.org/licenses/by-nc-nd/4.0/).
In this work, we fabricated poly(lactic-co-glycolic acid)
(PLGA), a biodegradable polymer approved by the US Food
and Drug Administration, into aligned nanofibers with
thickness 10- to 40-fold lower than previously reported
(Kharaziha et al., 2014; Masoumi et al., 2014; Han et al.,
2016; Joanne et al., 2016). Despite the low thickness, excel-
lent operability of nanofibers could be obtained by fixing
them on a silicone frame, which also enabled the establish-
ment of floating cultures. 3D cardiac tissue-like constructs
(CTLCs) were created by one-step seeding of high-purity
CMs derived from hPSCs (Minami et al., 2012) on the
aligned PLGA nanofibrous scaffold. The CMs within CTLCs
infiltrated and enveloped the nanofiber sheets, showing
elongation and high organization with upregulated expres-
sion of cardiac biomarkers and enhanced extracellular
recording,which is beneficial especially for drug assessment.
By engrafting CTLCs into the disconnected heart tissue
created in vitro or scarred heart tissue with re-entrant
arrhythmia, we also demonstrated the ability of CTLCs to
rapidly couple with the host tissue, which resulted in the
repair of the disconnected cardiac tissue and the suppression
of re-entrant arrhythmiaswithin the scarred region. Further-
more, the in vivo transplantation of CTLCs in an MI model
showed excellent CM survival and cardiac functional
improvement 4 weeks post surgery. Thus, CTLCs demon-
strated their potential for clinical use in the future.RESULTS
Cardiac Tissue-like Constructs Were Formed on
Aligned Nanofibers
The aligned PLGA nanofibers (ANFs) were used as a culture
scaffold to guide the growth and tissue formation of hiPSC-
CMs, because they resembled native extracellular matrix
(ECM) (Figure 1 and Figure S1) when compared with
randomly arranged PLGA nanofibers (RNFs) (Figure S1A)
and gelatin-coated flat substrates (Flat) used as control. To
mimic collagen fiber bundles in muscle tissue (Gillies and
Lieber, 2011) and produce the ECM-like pattern for engi-
neered cardiac tissue (Kim et al., 2010), the diameter of
the PLGA nanofibers was set at 500–2,000 nm (Figures
S1B and S1C) and the thickness at 1.5–12 mm by varying
the spinning time (Figures S1D and S1E). Despite the low
thickness of the nanofiber sheets, ANFs demonstrated
considerable flexibility (Movie S1) and anisotropic proper-
ties, which were evident not only in the structure but also
in Young’s modulus and wettability (Figures S1F–S1I).
Then, hiPSC-derived CMs were cultured on the prepared
substrates for 14 days. The samples were then examined by
electron microscopy (Figures 1E, 1H, 1I, S2A, and S2B) and
tomography (Figures 1F and 1G, Movies S2 and S3). Inter-
estingly, CMs could infiltrate and envelop both ANFs andRNFs because of the low thickness of nanofiber sheets (Fig-
ures 1F–1I and S1E), and the poly-dimethylsiloxane
(PDMS) frame can enable the floating culture of CMs,
which are both advantageous compared with methods
using 2D topographically aligned cues. The alignment of
large sarcomeric bundles could be observed only on
ANFs, while randomly distributed bundles were seen on
RNFs and Flat, indicating more mature sarcomeric organi-
zation of CMs on ANFs than the other two samples (Figures
1I, S2A, and S2B). Furthermore, dense CM sheets with
various thicknesses ranging from 36 ± 5 mm (n = 3) to 160
± 13 mm (n = 3) could be obtained by simply changing
the number of seeded cells (Figures 1J–1M), which
remained fully viable for 6 days after seeding (Figures S2C
and S2D). By increasing the cell number or overlayingmul-
tiple CM sheets, higher tissue thickness could be achieved
for transplantation. Because CM sheets on ANFs repro-
duced the in vivo arrangement, as demonstrated by their
highly defined 3D anisotropic structure, we designated
them as CTLCs.
Cardiomyocytes Demonstrated Improved Maturation
within Cardiac Tissue-like Constructs
CTLCs were further analyzed by flow cytometry, immuno-
staining, and qPCR. Flow cytometry analysis indicated that
before seeding, troponin T2 (cTnT)-positive CMs (253G1)
constituted 91.16% ± 4.96% (n = 32) of the total cell popu-
lation (Figures S2E and S2F). After 14 days of culture, the
proportions of cTnT-positive CMs on ANFs and RNFs are
86.79% ± 5.1% (n = 3) and 85.85% ± 9.11% (n = 3) respec-
tively, while that on Flat decreased dramatically to
71.101% ± 7.65% (n = 3) (Figure S2F), suggesting that other
cells outgrew CMs on flat substrates with no topographical
cue (Van Kooten et al., 1998). Moreover, immunostaining
for cardiac tissue-specific markers revealed significantly
higher expression of b-MHC, a cardiac maturity marker
correlated with contractile velocity (Nakao et al., 1997),
on ANFs than on Flat (Figure 2A). a-Actinin-positive sarco-
meres and cTnT-positive myofilaments were well defined
and positioned along ANFs, while a different arrangement
was observed on RNFs and Flat (Figures 2A, 2B, and S2G).
The analysis of mRNA expression revealed that several
genes were upregulated in CMs cultured on ANFs
compared with those cultured on other substrates (Fig-
ure 2C), including the genes involved in sarcomere struc-
tures (ACTN2, TNNT2, and TNNI3), cardiac maturation
(MYH7), ventricular structures (MYL2, HAND2), and
ER-Ca2+ function (PLN and RYR2). These findings were sup-
ported by hierarchical clustering analysis, which revealed
that the expression profile of CTLCs was distinct from
those of RNF- or Flat-grown cultures, in accordance with
their differences in sarcomeric organization revealed by
electron microscopy data (Figures 1I, S2A, and S2B).Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017 1547
Figure 1. Cardiac Tissue-like Constructs Formed on Aligned Nanofibers
(A) Schematic representation of the experimental approach.
(B) Scanning electron microscopy (SEM) image of aligned nanofibers (ANFs). Scale bar, 5 mm.
(C) Image of the ANFs transferred to a poly-dimethylsiloxane (PDMS) frame. Scale bar, 1 cm.
(D) Cross-section of the PDMS frame with ANFs after being cut in the middle. Scale bar, 1 cm.
(E) SEM image of cardiomyocytes (CMs) 14 days after seeding on ANFs. Scale bar, 10 mm.
(F and G) Tomography images of CTLCs obtained by cross-section scan (F) and top view scan (G). For more details, see Movies S2 and S3.
(H and I) Transmission electron microscopy images of CMs on ANFs. The green, red, and black arrows indicate the cross-section of
nanofibers, sarcomeric bundles, and Z bands in the actin-myosin system. Scale bars, 0.5 mm (H) and 2 mm (I).
(J–L) Histology of CTLCs with different cell seeding density: (J) 0.33 106 cells cm2; (K) 13 106 cells cm2; (L) 43 106 cells cm2.The
tissue cut was along the ANF alignment. Scale bar, 50 mm.
(M) Thickness of CTLCs with different cell density. Data are represented as means ±SD, n = 3 independent experiments. *p < 0.05,
***p < 0.001 by one-way ANOVA followed by Tukey’s post hoc test. See also Figures S1 and S2.Cardiac Tissue-like Constructs Showed Increased
Electrical Activity and Drug Response Compared with
Conventional 2D Cultures
Since CMs are contractile cells responsive to electrical
impulses, extracellular recording of spontaneous/st-
imulated electrical activity in contracting CMs can
provide assessment of their functional integrity. There-
fore, we compared the electrical characteristics of CMs
cultured on high-density ANFs (H-ANFs), low-density1548 Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017ANFs (L-ANFs), RNFs, and Flat (Figure 3 and Figure S3).
The larger amplitude of field potential (FP) observed for
CMs plated on ANFs and RNFs compared with those
grown on Flat indicated better cell attachment to nanofib-
ers (Figures 3B, 3C, and 3E). FP amplitude was lower for
the H-ANF than for the L-ANF samples; this was probably
due to a thicker fiber layer, which reduced the degree of
contact between CMs and electrodes, augmenting resis-
tance. The amplitude was increased from day 2 after cell
Figure 2. Enhanced Maturation of Cardiac Tissue-like Constructs
(A) Immunostaining images of b-MHC (red), and a-actinin and cTnT (green). Cardiomyocytes (CMs) were cultured on different substrates:
aligned nanofibers (ANFs), random nanofibers (RNFs), and gelatin-coated flat substrate (Flat); nanofibers were fabricated with green or red
dyes added before cell seeding. Scale bar, 50 mm.
(B) Fourier component analysis (FFT) of nuclei, nanofibers, and cTnT-positive thin filaments according to the positioning density on ANFs
(upper panel), RNFs (middle panel), and Flat (bottom panel).
(C) qPCR analysis of gene expression in CMs, relative to day 0: ACTN2 (a-actinin), TNNT2 (cTnT), TNNI3 (troponin I), MYH7 (myosin heavy
chain beta, b-MHC), MYL2 (ventricular myosin light chain-2), HAND2 (heart- and neural crest derivative-expressed protein 2), PLN
(phospholamban), and RYR2 (ryanodine receptor 2). The CMs were cultured for 14 days. Heatmap of Z score values shows genes expressed in
different groups. The FPKM (fragments per kilobase of exon per million fragments mapped) value of each gene is normalized using Z scores.
Data are represented as means ±SD, n = 3 independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA followed
by Tukey’s post hoc test.
See also Figure S2.seeding and reached a plateau between days 6 and 10,
indicating the developmental increase in the number
of electrically active, synchronized cardiac cells (Banach
et al., 2003).
Moreover, elliptical isochrones in the activation map of
the H-ANF and L-ANF samples indicated anisotropic prop-
agation of the electrical signal due to the direction-specific
orientation of CMs (Figure 3D). Notably, electrical propaga-
tion in the Flat sample started from a site other than the
stimuli site, suggesting weak attachment to electrodes
and low homogeneity of CMs (Figure S3D), which also oc-
casionally showed poor intercellular connectivity and
coupling (Figure S3E).
In our experiments, CMs on the Flat samples detached
from the electrodes after about 14 days because of poorer
cell attachment and homogeneity, which led to a lowerratio of T-wave-detecting channels in the microelectrode
array (MEA) (Figure 3F). However, CMs on thicker nanofib-
ers (H-ANFs) demonstrated a higher ratio of recorded chan-
nels and long-term (over 32 days) monitoring of CTLCs,
which is important for testing chronic drug effects on
CMs (Figure S4A).
The potential arrhythmia liability of a drug is required
to be assessed during cardiovascular drug screening and
toxicity testing. To evaluate drug effects on the electro-
physiological properties of CTLCs, E4031, a specific
blocker of the rapid component of the delayed rectifier
potassium current (IKr), was applied to different CM cul-
tures, which were then analyzed for QT interval duration,
used as an indicator of electric depolarization/repolariza-
tion of CMs. Significant QT interval prolongation was
observed for all three samples after E4031 treatmentStem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017 1549
Figure 3. Cardiac Tissue-like Constructs for More Appropriate Drug Assessment Compared with the 2D Flat Group
(A) Schematic representation of CTLCs on the microelectrode array (MEA) and a representative electrogram of the field potential (FP)
recorded from CMs illustrating the analyzed parameters.
(B) Spontaneous beatings of cardiomyocytes (CMs) on day 6 after seeding.
(C) Amplitude of CM field potential (FP) at different culture times (n = 4–5 independent biological replicates).
(D) Activation maps showing the propagation of stimulated contractility on day 6. The blue arrow demonstrates the propagation velocity.
(E) Overlapped FPs of CMs cultured on different substrates on day 6; colored arrows mark the QT intervals of different samples.
(F) Percentage of channels that recorded a T wave (n = 6–10 independent biological replicates).
(G) E4031 effects on corrected QT intervals of CMs (n = 3–5 independent biological replicates).
(H) Arrhythmia occurring after E4031 application on day 14.
(I) The ratio of samples with arrhythmia after E4031 application (100 nM) on day 14.
(J) Verapamil effects on corrected QT intervals of CMs (n = 3–5 independent biological replicates). Data are represented as means ±SD.
For (C), (F), and (J), *p < 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA followed by Tukey’s post hoc test. For (G), *p < 0.05,
**p < 0.01 by Student’s t test. Abbreviations: L-ANFs and H-ANFs, low-density and high-density aligned nanofibers, respectively; RNFs,
random nanofibers; Flat, gelatin-coated flat substrate. See also Figures S3–S5.(Figures 3G and S4B); however, the drug effects on Flat-
cultured CMs showed higher variability compared with
those observed in nanofiber-cultured CMs (Figure 3G).
In addition, E4031 caused more significant manifestations
of arrhythmia in the Flat-cultured than in the nanofiber-
cultured CMs (Figures 3H and 3I). Lower QT interval vari-
ability and less significant arrhythmic activity suggested
higher electrophysiological homogeneity of CMs cultured
on the nanofibers compared with those grown on Flat.
The analysis of CM chronotropic responses to isoproter-
enol and propranolol indicated that the former increased
the beat rate, while the latter blocked the stimulatory ef-
fect in all samples (Figures S4C and S4D). In addition,
0.03 mM Ca2+ channel blocker verapamil could lead to sig-
nificant shortening of the QT interval in all the nanofiber1550 Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017samples but not in Flat samples (Figures 3J and S5A). All
four samples demonstrated a similar drug response after
the addition of the sodium channel inhibitor quinidine
(Figures S5B and S5C). Overall, these data indicate that
the CTLC faithfully reproduced the in vivo structural and
functional properties of cardiac tissue and is, therefore, a
better model for drug cardiotoxicity testing than conven-
tional 2D CM cultures.
Cardiac Tissue-like Construct Engraftment Resulted in
Synchronization of Disconnected CM Tissue and
Suppression of the Re-entrant Spiral Wave
We next performed in vitro engraftment experiments to
characterize the ability of CTLCs to establish contacts and
couple with the host CM sheets. Two CTLCs engrafted
Figure 4. Cardiac Tissue-like Constructs
Can Synchronize Disconnected Cardio-
myocyte Tissues and Suppress Re-entrant
Arrhythmia within Scarred Cardiomyo-
cyte Sheets
(A) In vitro engraftment of two CTLC
samples. Histological section images show
a single CTLC (31) and two engrafted CTLCs
(32; 3 days after engraftment). Scale
bar, 50 mm.
(B) Engraftment of a CTLC on two discon-
nected sheets of GCaMP3-positive host
cardiomyocytes (CMs) on the microelec-
trode array (MEA) and recorded field po-
tential before and after engraftment. The
arrows mark the beating of the left host CM
sheet (red, recorded by electrode A), right
host CM sheet (green, recorded by electrode
B), and the CTLC (blue).
(C) Fluorescence images (left) and Ca2+
transients (right) of the two GCaMP3-posi-
tive (calcium sensor) host CM sheets before
and after CTLC engraftment. Complete
coupling was achieved at 81 ± 49 min
(means ± SD, n = 3 independent biological
replicates). For more details, see Movie S4.
Scale bar, 1 mm.
(D) Engraftment of the GCaMP3-positive
CTLC on a GCaMP3-positive host CM sheet
with spiral waves. Green and red arrows
indicate oscillations of the host CM
sheet and CTLC, respectively. The black
circle marks fast beating of the CTLC. Scale
bar, 1 s.
(E) A spiral wave (dashed line) is created in
the scarred host CM sheet. The yellow arrow
marks the propagation direction of GCaMP3
fluorescence. For more details, see Movie
S6. Scale bar, 1 mm.
See also Figure S6.together for 3 days were examined by histology, which
demonstrated the absence of a clear boundary between the
two samples and showed that the engrafted tissue was
2-fold thicker than a single CTLC layer (Figure 4A), indi-
cating rapid integration of the two CTLC samples. More-
over, a CTLC placed over two independently beating host
CM sheets separated by a barrier was able to synchronize
their contraction 81 ± 49 min (n = 3) after attachment
(Table 1), as indicated by the electrical signal of the MEA
and calcium sensor fluorescence protein GCaMP3 (Figures
4B and 4C and Movie S4). As a control test, the CMs were
also cultured on RNFs and placed on two independent
host CM sheets (Movie S5). Similarly, the CM sheets weresynchronized at 73.3 ± 18 min (n = 3) after attachment
(Table 1). These results indicate that the CTLC could inte-
grate with the host CM sheets and help establish rapid elec-
trical couplingbetweendisconnected areas in theheart, sug-
gesting potential for CTLCs to heal re-entrant cardiac
arrhythmias. To test this hypothesis, spiral waves were
induced in the GCaMP3-positive scarred cardiac host CM
sheet (Figures 4D and 4E andMovie S6) tomodel re-entrant
tachyarrhythmia (Kadota et al., 2013). Shortly after CTLC
attachment to the scarred tissue, we recorded two sets of cal-
cium signals: strong and relatively slow signals conducted
fromtheCTLC, andweakand fast re-entrant signals or spiral
wave of the host CM sheet. Slow acceleration of CTLCStem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017 1551
Table 1. Summary of Time for Cardiac Tissue-like Constructs to
Couple with Disconnected Tissues or Terminate the Spiral Wave
in Scarred Tissues
Coupling Time for CTLCs on
Disconnected Tissues
Time for CTLCs to Terminate
Spiral Wave in Scarred Tissues
ANF (n = 3
independent
biological
replicates)
RNF (n = 3
independent
biological
replicates)
ANF (n = 4
independent
biological
replicates)
RNF
81 ± 49 min 73.3 ± 18 min 129.5 ± 34 min NAbeating was due to the gradual coupling with the host CM
sheet, which was finally achieved at 129.5 ± 34 min (n = 4)
(Table 1 and Figure S6). Due to the coupling, the scar area,
where thepropagating spiralwavewaspinned,wasoverlaid,
and the spiral wave was able to propagate over rather than
around the scar, leading tounpinningand then termination
of the spiral waves.We further applied electrical stimulation
to induce a spiral wave in a scarred host CM sheet with
various engraftment (acellular nanofiber sheet and CTLC)
(Movie S7), finding that the spiral wave canonly be induced
in the acellular nanofiber sheet group but not in the CTLC
group. The data suggested that CTLC could effectively pre-
vent the recurrence of spiral wave. Moreover, the control
test with an RNF-CM sheet could not terminate the spiral
wave at 12 hr after attachment (Movie S6), indicating that
the aligned structure of CMsmay play a role in suppressing
the arrhythmia, and CTLCs have higher potential to alle-
viate cardiac arrhythmia.
Cardiac Tissue-like Constructs Integrated with the
Epicardium Improved the Function of the Infarcted
Heart
We analyzed and optimized the parameters for CTLC trans-
plantation (Figures S7A and S7B). CTLCs with 5–8 3 106
CMs were transplanted to the epicardium of the normal
nude rat ventricle for 2 weeks (Figure S7C), showing no
histological gaps (Figure 5A). The CTLC was monitored
by immunostaining for human TnT (hTnT), which was ex-
pressed in the transplanted CTLC but not in the recipient
rat heart (Figure 5B). Distinct thick clusters (390 ± 36 mm,
n = 3) of transplanted hTnT-positive CMs (96.6% ± 1.2%
of total cells [n = 3]; Figure S7D) were observed in the rat
hearts, while some hTnT-positive cells infiltrated the
epicardium of the rat ventricle (Figure 5B). In addition,
the alignment of CMs and organized compact sarcomeric
structures (Figures 5B and S7D) could be observed within
transplanted CTLC grafts. These results indicate the effi-
cient transplantation of CTLCs and the survival of hiPSC-
derived CMs for 14 days post transplantation.
Furthermore, CTLCs were delivered to the hearts of 12
rats with MI (Figures 5C and 5D); 17 MI rats received acel-1552 Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017lular nanofiber scaffolds as controls (Figure 5E). The im-
planted CTLCs were visible on the surface of the rat heart
at week 4 after transplantation (Figures 5C and 5D); in
contrast, acellular nanofiber scaffolds were hardly detect-
able (Figure 5E).
We also investigated the small blood vessels by using
CD31 immunostaining. The density of small vessels was
higher in the CTLC group than in the control group
(Figures 6A–6C). The baseline ejection fraction at week
0 did not differ significantly between the two groups
(p = 0.41); however, there was an increase in the ejection
fraction in rats treated with CTLCs at week 4 after trans-
plantation compared with week 0 (50.63% ± 6.41%,
n = 12, versus 37.50% ± 5.15%, n = 17, respectively), while
the ejection fraction in the control samples did not change
during the experiment (Figure 6D). The ejection fraction
values at 4 weeks after treatment was significantly different
between the two groups (p < 0.001).Moreover, transplanta-
tion with CTLC also improved the fractional shortening
(p < 0.001) and left ventricular end-systolic diameter
(LVESD) (p < 0.05) (Figures 6E and 6F). The left ventricular
end-diastolic diameter (LVEDD) demonstrated a significant
increase in the control group (p < 0.05) but not in the
CTLC group over 4 weeks (p = 0.95) (Figure 6G). CD68
immunostaining indicated that there were no obvious
inflammatory reactions in both groups at 4 weeks after
transplantation (Figures S7E and S7F). These results clearly
demonstrated functional improvement in the MI heart
provided by CTLCs due to the transplantation of func-
tional well-organized CMs.DISCUSSION
Cell therapy based on hPSC-derived CMs is a promising
approach for cardiac regeneration (Georgiadis et al.,
2014). Currently, efficient production of robust hPSC-
CMs is possible in serum-free conditions (Kattman et al.,
2011; Minami et al., 2012). However, the hPSC-CMs
obtained in 2D cultures morphologically and functionally
resemble immature CMs (Yang et al., 2014), as demon-
strated by their random sarcomere structure and distribu-
tion of the nuclei, lower expression of heart-specific genes,
decreased contractile force, and electrophysiological char-
acteristics different from those of adult CMs (Robertson
et al., 2013; Yang et al., 2014). These differences could
affect the functional properties and drug responses of
hPSC-CMs.
The problem could be solved by creating a nature-
mimicking environment, which would provide the appro-
priate biochemical and structural cues for CM maturation.
In this study, we used hPSC-derived CMs aligned on biode-
gradable PLGA nanofibers to generate tissue constructs
Figure 5. Cardiac Tissue-like Constructs Integrated with the Epicardium
(A–D) Histological sections of CTLCs after being transplanted on the rat heart without (A and B) or with myocardial infarction (MI)
(C and D). (A) and (B) were obtained at 2 weeks and (C) and (D) 4 weeks after transplantation. Scale bars in (A) and (C), 100 mm. (B and D)
Double immunostaining of consecutive sections of CTLCs after being transplanted on the rat heart without (B) or with (D) MI for hTnT
(green) and actin (white); nuclei were stained with DAPI (blue). The dashed line marks the CTLC boundary. The red arrows indicate that
hTnT-positive cardiomyocytes (CMs) infiltrated the epicardium of the rat ventricle. The white arrow indicates the alignment of CMs. Scale
bars in (B) and (D), 200 mm (left panel), 50 mm (right panel).
(E) Histological sections of MI heart with acellular nanofiber as control. Scale bars, 100 mm.
See also Figure S7.with morphological properties similar to those of the
myocardium (Kim et al., 2010), and avoided immunogenic
potential or ethical conflict compared with those methods
using decellularizedmyocardial slices (Schwan et al., 2016).
We also demonstrated that ANFs enhanced anisotropy
and 3D formation of CMs compared with RNFs and Flat
samples. Importantly, because of the low thickness of the
nanofiber sheets, CMs easily infiltrated and enveloped
the nanofibers.
Although compared with previous reports regarding CM
maturation, such as biowire (Nunes et al., 2013), nanopat-
tern (Pioner et al., 2016), dynamic culture (Jackman et al.,
2016), and engineered heart tissue (Mannhardt et al.,
2016), CTLCs, without any external physical stimulation,
do not show a higher maturation level of CMs, however,
their versatility and handy operability allows flexible appli-cations in both drug assessment and transplantation.
Furthermore, additional measures such as electrical/me-
chanical stimulation may be applied to further promote
CM maturation in CTLCs. Therefore, CLCTs could be an
important complement to present technologies.
We also demonstrated the potential of CTLCs in drug
screening. Previous single-cell- or cluster-based models
have shown heart-specific functional properties (Zwi
et al., 2009; Ma et al., 2011; Matsa et al., 2011); however,
single cells or small cell clusters do not reproduce the func-
tional activity of well-organized multicellular networks
existing in the heart and cannot serve as accurate models
to assess complex cardiac phenomena such as arrhythmia
(Kadota et al., 2013). The CTLC-MEA system offers a prom-
ising model for in vitro tissue-based drug screening as it
presents a 3D environment to promote the alignment,Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017 1553
Figure 6. Cardiac Tissue-like Constructs Improved the Function of the Infarcted Heart
(A and B) Capillary formation at the peri-ischemic zone in MI heart 4 weeks after transplantation of CTLCs (A) or acellular control (B).
The sections are immunostained with CD31. Scale bars, 100 mm.
(C) Quantification of the density of CD31-positive capillaries. Data are represented as means ± SD. CTLC, n = 7 rats; control, n = 6 rats.
*p < 0.05 by Student’s t test.
(D–G) Change of ejection fraction (D), fractional shortening (E), left ventricular end-systolic diameter (LVESD; F), and left ventricular end-
diastolic diameter (LVEDD; G) of infarct rat heart following CTLC transplantation versus the control group at 0 weeks and 4 weeks after
transplantation. Data are represented as means ± SD. CTLC, n = 12 rats; control, n = 17 rats. *p < 0.05 and ***p < 0.001 by one-way ANOVA
followed by Tukey’s post hoc test.
See also Figure S7.structural organization, and maturation of CMs, thus
mimicking the in vivo myocardium. The CTLC showed an
excellent response to the applied drugs (E4031, isopro-
terenol, verapamil, and quinidine) and demonstrated
decreased arrhythmia compared with the Flat sample at1554 Stem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017the same E4031 concentration. In addition, since hPSC-
CMs mature within 35 days (Snir et al., 2003), stable and
robust long-term CTLCs on the MEA chip could be
constantly monitored for CM maturation. Using other
biocompatible and nondegradable materials such as
polymethylglutarimide (PMGI) for nanofiber fabrication
(Li et al., 2016), the CTLC-MEA system could sustain CM
cultures over several months, which is the time required
for CM maturation according to a previous study (Kama-
kura et al., 2012). In short, the CTLC has proved to be an
accurate and robust model for screening drugs designed
for cardiovascular diseases.
We confirmed rapid electrical integration between the
CTLC and the host tissue by an in vitro test. The complete
coupling time (81 ± 49 min) was 2-fold higher than that
for rat CM tissue (Haraguchi et al., 2006), probably
because of considerable differences in the expression of
key ion channels, beating rates, and myofilament compo-
sition between rat and human CMs (Karakikes et al.,
2015). In addition, we reported that the coupling of tissue
grafts could unpin spiral waves in the infarcted cardiac
tissue, which previously could be achieved only by harm-
ful electrical stimulation (Tanaka et al., 2009; Feng et al.,
2014). The CTLC may be useful as an in vitro model
for the study of hPSC-CM engraftment and integration,
thus providing information for preclinical tests in
humans.
Moreover, the CTLC demonstrated sufficient degrad-
ability, operability, and robustness (Movie S1 and Figures
S7B, S7C, S7G, and S7H). Despite the high Young’s
modulus of PLGA nanofibers (Figure S1H), the nanofiber
sheets in this study had relatively low thickness
(12 mm), which is 10- to 40-fold lower than those in pre-
vious reports (Kharaziha et al., 2014; Masoumi et al.,
2014; Joanne et al., 2016) and may present an advantage
by reducing the risk of re-entrant arrhythmias (Bursac
et al., 2007) and inflammatory reactions. In addition,
the CTLC with high thickness (400 mm) integrated
with the host MI hearts and then improved their function
4 weeks after transplantation, which also proved that
when taking together the degradability, low thickness of
the fiber sheet, and the high thickness of CMs, the stiff-
ness of PLGA may not be a major issue for transplanta-
tion. These features together with the highly anisotropic
and dense organization of CMs as well as the practical
versatility make CTLCs clearly advantageous over previ-
ous transplantation with a CM-seeded nanofibrous scaf-
fold (Lin et al., 2014; Joanne et al., 2016). Compared
with the state-of-the-art temperature-responsive cell sheet
technique (Masumoto et al., 2012; Kawamura et al.,
2013), the one-step preparation and its one-step delivery
of high-thickness CMs sheet may make the CTLC an
important complement and alternative option.
Despite the improvement shown by CTLCs in regard to
both drug response and MI regeneration, it is still too early
to claim that the CTLC can be successfully used in drug
screening and regenerative medicine, since our data are
obtained based on transplantation in an MI rat modeland a limited number of drug types. In the future, a more
systematic drug screening should be performed to further
verify the robustness of CTLCs. Transplantations using a
clinically relevant large-animal model should be evaluated
for long-term effects.
In conclusion, we created organized and functional
CTLCs. Multilayered elongated CMs within the constructs
showed upregulated gene expression of cardiac markers,
enhanced extracellular recording, and robust drug
response. When used for engraftment, CTLCs demon-
strated excellent operability while enabling rapid coupling
and suppression of re-entrant arrhythmia in disconnected
or scarred tissue blocks. We also demonstrated post-surgery
cell survival in CTLCs and their ability to repair MI in a rat
model. Overall, the CTLCs have great potential for future
use in cell-based applications, including drug testing and
regenerative cardiac therapy.EXPERIMENTAL PROCEDURES
Differentiation and Culture of hiPSC-Derived CMs
hiPSCs (253G1, 201B7 [as noted in the legend]) and GCaMP3-pos-
itive hiPSCs (253G1) were maintained or generated as previously
reported (Hockemeyer et al., 2009; Shiba et al., 2012) and differen-
tiated according to the publishedmethod (Minami et al., 2012). All
experiments involving the use of hiPSCswere performed following
the Kyoto University guidelines. After 1–2 months of differe-
ntiation, floating colonies of CMs were collected and dispersed
into a single-cell suspension by stirring for 1–2 hr in protease solu-
tion: 0.1% collagenase type I, 0.25% trypsin, 1 U/mL DNase I,
116mMNaCl, 20mMHEPES, 12.5mMNaH2PO4, 5.6mMglucose,
5.4 mM KCl, and 0.8 mM MgSO4 (pH 7.35). After dispersion, the
cells were filtered through a 40-mm cell strainer (BD Falcon, USA)
and re-suspended at a density of 1 3 106 cells cm2 in serum-sup-
plemented cardiac differentiationmedium: IMDM(Sigma-Aldrich)
with 20% fetal bovine serum (FBS; Gibco), 1% MEM nonessential
amino acid solution (Sigma-Aldrich), 1% penicillin/streptomycin
(Gibco), 2 mM L-glutamine (Sigma-Aldrich), 0.001% 2-mercaptoe-
thanol (Gibco), and 0.005 N NaOH, with 10 ng/mL BMP4 (R&D
Systems), and plated on ANFs, RNFs, or 0.1% gelatin-coated flat
substrates (Flat). The medium was changed to serum-free medium
(cardiac differentiationmediumwithout FBS) every 4 days starting
from day 2.In Vitro Engraftment
CTLCs were created by seeding regular or GCaMP3-positive CMs
on H-ANFs at a density of 1 3 106 cells cm2. The RNF-CM sheets
were created by seeding the same density of CMs on RNFs. The
disconnected CM sheets were created by seedingGCaMP3-positive
CMs at the same density on the substrate within a 5-mm PDMS
ring, and sheets A and Bwere isolated by a 200-mm-wide PDMS bar-
rier; the barrier was removed 2 days after seeding. Host CM sheets
with spiral waves were prepared by seeding GCaMP3-CMs on
gelatin-coated flat substrates at the same density and inflicting a
5-mm scar by abrasion; spiral waves were initiated by rapid pacingStem Cell Reports j Vol. 9 j 1546–1559 j November 14, 2017 1555
(Isomura et al., 2008) at frequencies ranging from 2 to 4 Hz with a
stimulus generator (Multi Channel Systems). The CTLCswere used
for engraftment 5–6 days after seeding.
In Vivo Transplantation
Animal experiments were approved by the ethics committee of
Osaka University and were performed following the committee’s
guidelines. For the transplantation test on normal heart, 8-week-
old male nude rats (CLEA Japan, Japan) were used for transplanta-
tion. To create an MI model, thoracotomy was performed between
the fourth and fifth intercostal spaces, andMI was induced by liga-
tion of the left coronary artery, as described previously (Memon
et al., 2005). HiPSC-CMs (5–8 3 106 cells) were seeded on the
H-ANFs in a 1 3 1 cm2 PDMS frame for 1 day. Before transplanta-
tion, cells were treated with 5 mg cm2 of Cellnest recombinant
peptide based on human collagen type I (Fujifilm, Japan) at
room temperature for 5 min; then, the PDMS frame was cut, and
the CTLCs were placed on the epicardium and covered with Beri-
plast P (CSL Behring, USA). Echocardiography was performed us-
ing an ultrasound machine (SONOS 5500, Agilent Technologies)
equipped with an annular array transducer operating at 12 MHz
(Memon et al., 2005). The ejection fraction (EF) was calculated
using the following formula: EF (%) = (LVEDD3  LVESD3)/
LVEDD3 3 100 (%). Rats without and with MI were killed at
14 days and 4 weeks post surgery, respectively, and the hearts
were harvested and used to prepare 7-mm-thick cryosections for
histology and immunostainingwith an anti-TnTantibody (Abcam
Plc) and phalloidin; cell nuclei were stained with DAPI (Life
Technologies).
Statistical Analysis
All quantitative data are presented as the mean ± SD. The differ-
ence between two groups was analyzed by one-tailed Student’s
t test, and p < 0.05was considered statistically significant. Compar-
ison tests among multiple groups were analyzed by one-way
ANOVA followed by Tukey’s post hoc test, and p < 0.05 was consid-
ered statistically significant.
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